Sacroiliac; BackacheTriPalNCT05043961
Palisade Lateral Branch Technique Using Multi-tined Needles for Sacro-iliac Joint Radiofrequency Ablation
An observational study of Sacroiliac; Backache and Chronic Pain, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
Trial summary
The sacro-iliac joint is a large joint that can be the source of chronic pain. Many treatment options have been proposed to treat SIJ pain, with variable efficacy. The next step in managing those patients who can't get sustained pain relief from conservative treatment is radiofrequency ablation (RFA) of the SIJ's… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sacroiliac; Backache, Chronic Pain
- What is being tested?
- Palisade sacroiliac joint radiofrequency ablation using 3-tined needles
- Type of treatment
- Injection or infusion, Surgery or procedure
- How many people
- 12 participants
- Where
- 1 siteCanada
- Study dates
- 1 Jun 2022to 11 Feb 2025
- How long will I take part?
- 10 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who are candidates for sacroiliac joint radio frequency ablation at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic
Who may be able to join
- 18 years and older
- Low back pain caused by SIJ dysfunction lasting > 6 months:
- Predominantly axial pain below the L5 vertebrae with an average daily Verbal Numercial Scale Score (VNS) >4;
- >50% pain relief after a fluoroscopically guided intraarticular injection of local anesthetic and steroids in the SIJ but lasting less than 3 months. Injection performed in the last 6 months prior to enrollment.
Who cannot join
- Pregnancy
- Spinal pathology that may impede recovery such as severe spondylolisthesis at L5/S1, severe scoliosis, or lumbar fusion;
- Active radicular pain;
- Worker's compensation;
- Cognitive limitation or linguistic barrier making pain assessment through questionnaire impossible;
- Implanted pacemaker or defibrillator;
- Refusal.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Determination of the Success Rate of the Palisade Lateral Branch Technique Using Multi-tined Needles for Sacro-iliac Joint Radiofrequency Ablation
The sacro-iliac joint is a large joint that can be the source of chronic pain. Many treatment options have been proposed to treat SIJ pain, with variable efficacy. The next step in managing those patients who can't get sustained pain relief from conservative treatment is radiofrequency ablation (RFA) of the SIJ's posterior innervation.
However, the success rate of SIJ RFA, as determined by the proportion of patients reporting greater than 50% pain relief 6 months after the intervention, varies substantially across studies, ranging from 38-71 %. This may be explained partly by the fact that there may be incomplete lesioning of the target nerves supplying the joint. To overcome these particularities, two RFA techniques have emerged: cooled RFA and bipolar RFA.
Read more
Cooled radiofrequency is the one that has been studied the most, and good evidence supports its efficacy. However, its superiority to conventional RF for the treatment of SIJ pain is not confirmed.
Alternatively, a bipolar RFA technique using conventional radiofrequency needles and equipment can be used. The efficacy of this relatively newer technique has been demonstrated by only one study, and although the results were promising, it is not known whether they could be replicated. The success of the palisade technique could be enhanced by using multi-tined expandable electrodes, such as the 3-tined Trident cannulas, with only small increases in cost.
In clinical practice, the palisade technique using 3-tines needles is routinely used. However, its efficacy has not been formally evaluated. The primary objective of this prospective cohort study will be to determine the success rate of the palisade SIJ RFA (P-RF) technique using the 3-tined needles, determined as the proportion of patients reporting >50% pain relief, 6 months after the procedure.
Read the detailed description
Single center, prospective cohort study. all patients presenting to the Maisonneuve-Rosemont's Pain center with chronic low back pain of SIJ origin who are candidates for SIJ RFA during a two year period will be invited to participate in this study. SIJ RFA will be performed using the palisade technique using 3-tined needles. The patients will be followed for a period of 10 months to determine pain relief, opioid use, satisfaction and impact on disability.
Study design: Prospective, cohort study Population: Patients who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic Duration of study: 2 years Patient included in the study will be followed up for 10 months. Sample size: Approximately 30 patients (anticipated)
General Study procedure This study's methodology will follow the standard practice for treating patients with SIJ pain at the Maisonneuve-rosemont Hospital First, an intraarticular SIJ injection of local anesthetic with a corticosteroid is offered to patients presenting with pain of presumed SIJ origin (predominantly axial low back pain, below the L5 vertebrae, positive SIJ provocation maneuvers). Patients who experience significant pain relief but lasting less than 3 months are offered a SLBB. According to standard practice, all patients receiving a SLBB file a pain diary that evaluates the pain intensity over a 36h period following the block (see Annex 1). This diary is sent back by e-mail to the treating physician and will be deemed positive if >50% pain relief is reported for at least 2h but lasting less than 24h. Patients with a positive SLBB are always considered for SIJ RFA. Patients with a negative SLBB may or may not undergo SIJ RFA, depending on the treating physician. Indeed, although SLBB have been suggested as a more appropriate method for selecting patients who should undergo SIJ RFA, its predictive value has not been formally evaluated and many physicians feel that not performing SIJ RFA in patients with negative SLBB may lead to withholding an effective treatment from patients. Thus, the standard practice is to proceed with SIJ RFA even with a negative SLBB because its prognostic value is not clear.
For the purpose of this study, all patients experiencing >50% pain relief after an intra articular SIJ injection of local anesthetic and corticosteroid but lasting less than 3 months and who wish to undergo SIJ RFA, as suggested by their treating physician, will be considered for inclusion in the study. Then, following general procedure, all patients will undergo a SLBB performed according to the previously described technique. The data from all the diaries will be collected to determine the rate of positive SLBBs among patients who had significant but not sustained pain relief from intraarticular SIJ injection. Then, all patients will proceed to SIJ RFA.
Recrutement:
Physicians will inform the research nurse when they meet a patient who had significant but non sustained pain relief after a SIJ injection and for which they consider SIJ RFA to be the next step in treatment.
The patient's file will be reviewed to confirm inclusion and exclusion criteria. All eligible patients will then be contacted by phone by a member of the research team to introduce them to the study protocol. A copy of the patient consent form will be sent by e-mail to patients who show interest in participating to the research project.
Patients will then be contacted again by phone the day prior to the procedure to answer any question and confirm their interest in participating to the study. Patients who wish to participate will be met by the research team on the day of their procedure and written consent will be obtained.
RF Procedure:
All procedures will be performed according to the standard of care for SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic.
P-RF:
P-RF is performed using a conventional temperature-controlled RF generator (Diros Technology Inc's OWL, Markham, ON, Canada) generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar output.
Lesioning the sacral lateral branches:
- Under fluoroscopic guidance in the anteroposterior view, the C-arm is angulated cephalad in order to align the superior end plate of S1.
- Using a radiopaque marker, the superior border of the S1 posterior foramen is identified and the marker is placed slightly superior to this level, between the posterior foramen lateral border and the SIJ line. The overlying skin is marked with a sterile pen. The same marking procedure is accomplished, slightly inferior to the inferior border of the S3 posterior foramen. Using a sterile disposable ruler, a line connecting these two dots is drawn on the patient's skin and marked every 10 millimeters. The resulting line will typically be 55-60 mm long, and can be extended 5 mm in its superior and/or inferior part to allow sufficient space to place the uppermost and/or lowermost needle, allowing an inter-needle distance of 10 mm
- The skin is anesthetized with 1% lidocaine at each of the 10 mm marks, and four 3-tined RF needles are inserted under fluoroscopic guidance at the four uppermost marks. Intermittent fluoroscopy is used to ensure that the needles stay parallel to one another, perpendicular to the dorsal surface of the sacrum.
- Once contact with the dorsal surface of the sacrum is obtained, the C-arm is turned to obtain a lateral view to confirm that none of the needles went into the sacral foramen or landed on the posterior iliac crest (too shallow), and the tines are deployed.
- The four needles are connected to the four outputs of the quadripolaire radiofrequency generator. A motor stimulation test is carried out at each of the needles to ensure absence of motor stimulation in the lower limbs (2.0 V, 2 Hz), and 0,5 ml of 1% lidocaine is injected through the side port of each cannula. The RF energy is then delivered, making one quadripolar lesion. Then, the three uppermost cannulas are removed and two cannulas are inserted at the fifth and sixth mark, using the same technique as previously described, and two more sets of bipolar lesions are created, sequential (between needles 4 and 5, and then between 5 and 6) This procedure thus requires a total of 3 outputs of RF energy.
Lesioning the L5 dorsal ramus:
-Under fluoroscopic guidance in the anteroposterior view, the inflexion between the ala of the sacrum and the S1 superior articular process, is visualized. The RF needle is inserted from a point slightly lateral and inferior to the target until contact with the bone is made. Using a lateral view, the needle is confirmed to be no deeper than the anterior-posterior midline of the S1 superior articular process. The tines are deployed, and motor testing is performed to ensure absence of motor stimulation in the lower limb (2.0 V, 2 Hz). Sensory testing will not be performed as its benefits regarding clinical outcome are not endorsed by clinical guidelines. Then, 1 ml of 1% lidocaine is injected through the side port and the RF energy is delivered, creating a monopolar lesion.
Data collection
Baseline demographic data: Questionnaires will be answered by the patients in person, before the procedure.
Age, sex; Uni or bilateral lesioning; Average pain intensity over the last 7 days (Verbal Numeric scale score 0-10, where 0: no pain at all and 10: worse imaginable pain); Duration of pain (months); Smoking status; Opioid use and daily Oral Morphine Equivalent (OME); Fibromyalgia survey score (Widespread Pain Index + Symptom Severity Scale (Score /31)); Hospital Anxiety and Depression Score (HADS) Oswestry Disability Index score (ODI), Result (positive or negative) of the multi-site, multi-depth, sacral lateral branch block performed with 2% lidocaine. Positive= >50% pain relief for a duration of 2-24h, using a 36h pain diary evaluating pain intensity.
Follow up data
Patients will answer the questionnaires either in person at the Pain Clinic or from their home. In this case, patients will be contacted by phone at the time of the follow up to:
- Evaluate the average pain intensity over the last 7 days (VNS);
- Inform them that questionnaires were sent by e-mails and that they need to be completed and returned to the research team. Reminders will be sent after 2 and 4 weeks. 1 month:
- Average pain intensity over the last 7 days (VNS 0-10). 3, 6 and 10 months:
- Average pain intensity over the last 7 days (VNS 0-10);
- Success (O/N), defined as >50% pain relief, compared to baseline;
- Patient Global Impression of Change Score (PGIC);
- ODI score;
- Opioid use over the last 7 days (yes/no).
- Conditions
- Sacroiliac; Backache, Chronic Pain
- Being tested
- Palisade sacroiliac joint radiofrequency ablation using 3-tined needles
- Keywords
- radiofrequency ablation, Sacroiliac joint pain, chronic pain
- Medical subject headings
- Back Pain, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Palisade sacroiliac joint radiofrequency ablation using 3-tined needlesProcedure or surgery
Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.
The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.
Lesioning the L5 dorsal ramus:
- The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion.
| Study group | Role | What they receive |
|---|---|---|
| study group | Patients who report >50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study.
Intervention:
Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles Receives: Procedure: Palisade sacroiliac joint radiofrequency ablation using 3-tined needles |
What is being measured
The primary outcome is the main question the study is designed to answer.
Success rate
proportion of patients reporting >50% pain relief
Measured: 6 months
Secondary outcomes (16)
Succes rate
proportion of patients reporting >50% pain relief
Measured: 3 months
Succes rate
proportion of patients reporting >50% pain relief
Measured: 1 month
Succes rate
proportion of patients reporting >50% pain relief
Measured: 10 month
Change in Pain score
mean change in pain score using a verbal numeric pain scale of 0-10 (0: no pain, 10: worse imaginable pain)
Measured: 1 month
Change in Pain score
mean change in pain score using a verbal numeric pain scale of 0-10 (0: no pain, 10: worse imaginable pain)
Measured: 3 month
Change in Pain score
mean change in pain score using a verbal numeric pain scale of 0-10 (0: no pain, 10: worse imaginable pain)
Measured: 6 month
Chang in Pain score
mean change in pain score using a verbal numeric pain scale of 0-10 (0: no pain, 10: worse imaginable pain)
Measured: 10 month
Impact on disability
change in the Owestry Disability Index (scale 0-100 where 0: minimal disability, 100: crippled)
Measured: 3 months
Impact on disability
change in the Owestry Disability Index (scale 0-100 where 0: minimal disability, 100: crippled)
Measured: 6 months
Impact on disability
change in the Owestry Disability Index (scale 0-100 where 0: minimal disability, 100: crippled)
Measured: 10 months
Impact on improvement
Patient global impression of change scale score (scale of 1-7 where 1: very much improved, 7: very much worse
Measured: 3 months
Impact on improvement
Patient global impression of change scale score (scale of 1-7 where 1: very much improved, 7: very much worse
Measured: 6 months
Impact on improvement
Patient global impression of change scale score (scale of 1-7 where 1: very much improved, 7: very much worse
Measured: 10 months
Opioid use
determine the impact of the intervention on the opioid daily dose(determined by calculating Oral Morphine Equivalent)(mg)
Measured: 3 months
Opioid use
determine the impact of the intervention on the opioid daily dose (determined by calculating Oral Morphine Equivalent)(mg)
Measured: 6 months
Opioid use
determine the impact of the intervention on daily opioid dose (determined by calculating Oral Morphine Equivalent)(mg)
Measured: 10 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2021
- Study start1 Jun 2022
- Primary completion1 Dec 2024
- Study completion11 Feb 2025
Why it stopped: Not enough study participants
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sacroiliac; BackacheStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (actual)
- Target duration
- 10 Months
Sponsor and investigators
- Lead sponsor
- Ciusss de L'Est de l'Île de Montréal
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Veronique Brulotte, Maisonneuve-Rosemont Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05043961
- Sponsor's protocol ID
- 2022-2704
- Acronym
- TriPal
- Status last verified
- Feb 2025
- First submitted
- 2 Sep 2021
- Last updated
- 13 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determination of the Success Rate of the Palisade Lateral Branch Technique Using Multi-tined Needles for Sacro-iliac Joint Radiofrequency Ablation
- ClinicalTrials.gov ID
- NCT05043961
- Acronym / sponsor ID
- TriPal / 2022-2704
- Conditions
- Sacroiliac; Backache, Chronic Pain
- Keywords
- radiofrequency ablation, Sacroiliac joint pain, chronic pain
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Not enough study participants
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Ciusss de L'Est de l'Île de MontréalUniversity, hospital or other
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 1 Dec 2024 (actual)
- Study completion
- 11 Feb 2025 (actual)
- First posted
- 14 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The sacro-iliac joint is a large joint that can be the source of chronic pain. Many treatment options have been proposed to treat SIJ pain, with variable efficacy. The next step in managing those patients who can't get sustained pain relief from conservative treatment is radiofrequency ablation (RFA) of the SIJ's posterior innervation.
However, the success rate of SIJ RFA, as determined by the proportion of patients reporting greater than 50% pain relief 6 months after the intervention, varies substantially across studies, ranging from 38-71 %. This may be explained partly by the fact that there may be incomplete lesioning of the target nerves supplying the joint. To overcome these particularities, two RFA techniques have emerged: cooled RFA and bipolar RFA.
Cooled radiofrequency is the one that has been studied the most, and good evidence supports its efficacy. However, its superiority to conventional RF for the treatment of SIJ pain is not confirmed.
Alternatively, a bipolar RFA technique using conventional radiofrequency needles and equipment can be used. The efficacy of this relatively newer technique has been demonstrated by only one study, and although the results were promising, it is not known whether they could be replicated. The success of the palisade technique could be enhanced by using multi-tined expandable electrodes, such as the 3-tined Trident cannulas, with only small increases in cost.
In clinical practice, the palisade technique using 3-tines needles is routinely used. However, its efficacy has not been formally evaluated. The primary objective of this prospective cohort study will be to determine the success rate of the palisade SIJ RFA (P-RF) technique using the 3-tined needles, determined as the proportion of patients reporting >50% pain relief, 6 months after the procedure.
Detailed description
Single center, prospective cohort study. all patients presenting to the Maisonneuve-Rosemont's Pain center with chronic low back pain of SIJ origin who are candidates for SIJ RFA during a two year period will be invited to participate in this study. SIJ RFA will be performed using the palisade technique using 3-tined needles. The patients will be followed for a period of 10 months to determine pain relief, opioid use, satisfaction and impact on disability.
Study design: Prospective, cohort study Population: Patients who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic Duration of study: 2 years Patient included in the study will be followed up for 10 months. Sample size: Approximately 30 patients (anticipated)
General Study procedure This study's methodology will follow the standard practice for treating patients with SIJ pain at the Maisonneuve-rosemont Hospital First, an intraarticular SIJ injection of local anesthetic with a corticosteroid is offered to patients presenting with pain of presumed SIJ origin (predominantly axial low back pain, below the L5 vertebrae, positive SIJ provocation maneuvers). Patients who experience significant pain relief but lasting less than 3 months are offered a SLBB. According to standard practice, all patients receiving a SLBB file a pain diary that evaluates the pain intensity over a 36h period following the block (see Annex 1). This diary is sent back by e-mail to the treating physician and will be deemed positive if >50% pain relief is reported for at least 2h but lasting less than 24h. Patients with a positive SLBB are always considered for SIJ RFA. Patients with a negative SLBB may or may not undergo SIJ RFA, depending on the treating physician. Indeed, although SLBB have been suggested as a more appropriate method for selecting patients who should undergo SIJ RFA, its predictive value has not been formally evaluated and many physicians feel that not performing SIJ RFA in patients with negative SLBB may lead to withholding an effective treatment from patients. Thus, the standard practice is to proceed with SIJ RFA even with a negative SLBB because its prognostic value is not clear.
For the purpose of this study, all patients experiencing >50% pain relief after an intra articular SIJ injection of local anesthetic and corticosteroid but lasting less than 3 months and who wish to undergo SIJ RFA, as suggested by their treating physician, will be considered for inclusion in the study. Then, following general procedure, all patients will undergo a SLBB performed according to the previously described technique. The data from all the diaries will be collected to determine the rate of positive SLBBs among patients who had significant but not sustained pain relief from intraarticular SIJ injection. Then, all patients will proceed to SIJ RFA.
Recrutement:
Physicians will inform the research nurse when they meet a patient who had significant but non sustained pain relief after a SIJ injection and for which they consider SIJ RFA to be the next step in treatment.
The patient's file will be reviewed to confirm inclusion and exclusion criteria. All eligible patients will then be contacted by phone by a member of the research team to introduce them to the study protocol. A copy of the patient consent form will be sent by e-mail to patients who show interest in participating to the research project.
Patients will then be contacted again by phone the day prior to the procedure to answer any question and confirm their interest in participating to the study. Patients who wish to participate will be met by the research team on the day of their procedure and written consent will be obtained.
RF Procedure:
All procedures will be performed according to the standard of care for SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic.
P-RF:
P-RF is performed using a conventional temperature-controlled RF generator (Diros Technology Inc's OWL, Markham, ON, Canada) generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar output.
Lesioning the sacral lateral branches:
- Under fluoroscopic guidance in the anteroposterior view, the C-arm is angulated cephalad in order to align the superior end plate of S1.
- Using a radiopaque marker, the superior border of the S1 posterior foramen is identified and the marker is placed slightly superior to this level, between the posterior foramen lateral border and the SIJ line. The overlying skin is marked with a sterile pen. The same marking procedure is accomplished, slightly inferior to the inferior border of the S3 posterior foramen. Using a sterile disposable ruler, a line connecting these two dots is drawn on the patient's skin and marked every 10 millimeters. The resulting line will typically be 55-60 mm long, and can be extended 5 mm in its superior and/or inferior part to allow sufficient space to place the uppermost and/or lowermost needle, allowing an inter-needle distance of 10 mm
- The skin is anesthetized with 1% lidocaine at each of the 10 mm marks, and four 3-tined RF needles are inserted under fluoroscopic guidance at the four uppermost marks. Intermittent fluoroscopy is used to ensure that the needles stay parallel to one another, perpendicular to the dorsal surface of the sacrum.
- Once contact with the dorsal surface of the sacrum is obtained, the C-arm is turned to obtain a lateral view to confirm that none of the needles went into the sacral foramen or landed on the posterior iliac crest (too shallow), and the tines are deployed.
- The four needles are connected to the four outputs of the quadripolaire radiofrequency generator. A motor stimulation test is carried out at each of the needles to ensure absence of motor stimulation in the lower limbs (2.0 V, 2 Hz), and 0,5 ml of 1% lidocaine is injected through the side port of each cannula. The RF energy is then delivered, making one quadripolar lesion. Then, the three uppermost cannulas are removed and two cannulas are inserted at the fifth and sixth mark, using the same technique as previously described, and two more sets of bipolar lesions are created, sequential (between needles 4 and 5, and then between 5 and 6) This procedure thus requires a total of 3 outputs of RF energy.
Lesioning the L5 dorsal ramus:
-Under fluoroscopic guidance in the anteroposterior view, the inflexion between the ala of the sacrum and the S1 superior articular process, is visualized. The RF needle is inserted from a point slightly lateral and inferior to the target until contact with the bone is made. Using a lateral view, the needle is confirmed to be no deeper than the anterior-posterior midline of the S1 superior articular process. The tines are deployed, and motor testing is performed to ensure absence of motor stimulation in the lower limb (2.0 V, 2 Hz). Sensory testing will not be performed as its benefits regarding clinical outcome are not endorsed by clinical guidelines. Then, 1 ml of 1% lidocaine is injected through the side port and the RF energy is delivered, creating a monopolar lesion.
Data collection
Baseline demographic data: Questionnaires will be answered by the patients in person, before the procedure.
Age, sex; Uni or bilateral lesioning; Average pain intensity over the last 7 days (Verbal Numeric scale score 0-10, where 0: no pain at all and 10: worse imaginable pain); Duration of pain (months); Smoking status; Opioid use and daily Oral Morphine Equivalent (OME); Fibromyalgia survey score (Widespread Pain Index + Symptom Severity Scale (Score /31)); Hospital Anxiety and Depression Score (HADS) Oswestry Disability Index score (ODI), Result (positive or negative) of the multi-site, multi-depth, sacral lateral branch block performed with 2% lidocaine. Positive= >50% pain relief for a duration of 2-24h, using a 36h pain diary evaluating pain intensity.
Follow up data
Patients will answer the questionnaires either in person at the Pain Clinic or from their home. In this case, patients will be contacted by phone at the time of the follow up to:
- Evaluate the average pain intensity over the last 7 days (VNS);
- Inform them that questionnaires were sent by e-mails and that they need to be completed and returned to the research team. Reminders will be sent after 2 and 4 weeks. 1 month:
- Average pain intensity over the last 7 days (VNS 0-10). 3, 6 and 10 months:
- Average pain intensity over the last 7 days (VNS 0-10);
- Success (O/N), defined as >50% pain relief, compared to baseline;
- Patient Global Impression of Change Score (PGIC);
- ODI score;
- Opioid use over the last 7 days (yes/no).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| study group | – | Procedure: Palisade sacroiliac joint radiofrequency ablation using 3-tined needlesPatients who report >50% pain relief after an intra articular sacroiliac joint injection but lasting less than 3 months who are scheduled to receive a SIJ RFA at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic and who meet inclusion criteria will be offered to participate in this study. Intervention: Sacroiliac joint rafiofrequency ablation using the bipolar palissade approach and 3-tined needles |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who are candidates for sacroiliac joint radio frequency ablation at the Maisonneuve-Rosemont Hospital's Chronic Pain Clinic
Key inclusion criteria (4 listed)
- 18 years and older
- Low back pain caused by SIJ dysfunction lasting > 6 months:
Key exclusion criteria (7 listed)
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Palisade sacroiliac joint radiofrequency ablation using 3-tined needlesPalisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output. The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned. Lesioning the L5 dorsal ramus: o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion. | Procedure or surgery | study group |
Primary outcome
Success rate
Time frame: 6 months
proportion of patients reporting >50% pain relief
16 secondary outcomes
Succes rate
Time frame: 3 months
Succes rate
Time frame: 1 month
Succes rate
Time frame: 10 month
Change in Pain score
Time frame: 1 month
Change in Pain score
Time frame: 3 month
Change in Pain score
Time frame: 6 month
Chang in Pain score
Time frame: 10 month
Impact on disability
Time frame: 3 months
Impact on disability
Time frame: 6 months
Impact on disability
Time frame: 10 months
Impact on improvement
Time frame: 3 months
Impact on improvement
Time frame: 6 months
Impact on improvement
Time frame: 10 months
Opioid use
Time frame: 3 months
Opioid use
Time frame: 6 months
Opioid use
Time frame: 10 months
Results and safety
The study was stopped early (reason given: Not enough study participants). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2025.
Related trials for Sacroiliac; Backache
Not yet recruiting
Comparison of High-Intensity and Conventional Physical Therapy in Musculoskeletal Disorders
Low Back Pain, Radicular Syndrome
Recruiting
Analgesic Effect of Sacral Submultifidus Block as an Adjunct to Sacroiliac Joint Injection
Sacro Iliac Joint Pain, Low Back Pain
Not yet recruiting
Image-Guided Intra-Articular Versus Periarticular Injection in Sacroiliac Joint Pain
Sacroiliac Joint Pain, Sacroiliac Joint Dysfunction
Recruiting
Comparison of Core Stability and Hip Strengthening Protocols in Sacroiliac Joint Dysfunction
Sacroiliac Joint Dysfunction
Not yet recruiting
Neurolyser XR for the Treatment of Sacroiliitis
Sacroiliitis, Low Back Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sacroiliac; Backache and Chronic Pain, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 13 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Not enough study participants). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Success rate (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2025.